Jean‐Pierre Bleuse

735 total citations
21 papers, 468 citations indexed

About

Jean‐Pierre Bleuse is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jean‐Pierre Bleuse has authored 21 papers receiving a total of 468 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 5 papers in Surgery and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jean‐Pierre Bleuse's work include Cancer Treatment and Pharmacology (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Breast Cancer Treatment Studies (3 papers). Jean‐Pierre Bleuse is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Breast Cancer Treatment Studies (3 papers). Jean‐Pierre Bleuse collaborates with scholars based in France and United States. Jean‐Pierre Bleuse's co-authors include William Jacot, Gilles Romieu, Simon Thézenas, Pierre‐Jean Lamy, Marion Carayol, Grégory Ninot, H Sancho-Garnier, Pierre Sénesse, Evelyne Lopez‐Crapez and Frédéric Bibeau and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

Jean‐Pierre Bleuse

21 papers receiving 461 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jean‐Pierre Bleuse France	11	309	125	109	84	63	21	468
Bella Pajares Spain	13	291 0.9×	174 1.4×	53 0.5×	195 2.3×	112 1.8×	37	592
Michaela Onstad United States	10	304 1.0×	177 1.4×	55 0.5×	158 1.9×	50 0.8×	24	736
Lorenzo Rossi Switzerland	10	192 0.6×	99 0.8×	34 0.3×	90 1.1×	110 1.7×	30	402
Emily K. Tam United States	10	172 0.6×	43 0.3×	70 0.6×	58 0.7×	24 0.4×	20	477
C. Seynaeve Netherlands	16	299 1.0×	168 1.3×	90 0.8×	52 0.6×	163 2.6×	37	668
Eulàlia Urgell Spain	12	226 0.7×	181 1.4×	113 1.0×	109 1.3×	55 0.9×	27	465
Eun Young Kang South Korea	13	124 0.4×	80 0.6×	63 0.6×	61 0.7×	56 0.9×	45	424
Tara Spivey United States	9	151 0.5×	81 0.6×	59 0.5×	40 0.5×	35 0.6×	15	391
Eric K. Singhi United States	9	152 0.5×	61 0.5×	42 0.4×	116 1.4×	134 2.1×	26	471
Shengyang Qiu United Kingdom	11	223 0.7×	82 0.7×	60 0.6×	112 1.3×	88 1.4×	22	457

Countries citing papers authored by Jean‐Pierre Bleuse

Since Specialization

Citations

This map shows the geographic impact of Jean‐Pierre Bleuse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Pierre Bleuse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Pierre Bleuse more than expected).

Fields of papers citing papers by Jean‐Pierre Bleuse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Pierre Bleuse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Pierre Bleuse. The network helps show where Jean‐Pierre Bleuse may publish in the future.

Co-authorship network of co-authors of Jean‐Pierre Bleuse

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Pierre Bleuse. A scholar is included among the top collaborators of Jean‐Pierre Bleuse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Pierre Bleuse. Jean‐Pierre Bleuse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Adenis, Antoine, François Ghiringhelli, Thibault Mazard, et al.. (2022). Regorafenib (REGO) plus FOLFIRINOX as frontline treatment in patients (pts) with RAS-mutated metastatic colorectal cancer (mCRC): A phase I/II, dose-escalation and dose-expansion study.. Journal of Clinical Oncology. 40(16_suppl). 3561–3561. 1 indexed citations

Ho-Pun-Cheung, Alexandre, Hervé Bazin, Florence Boissière‐Michot, et al.. (2019). Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples. British Journal of Cancer. 122(3). 397–404. 12 indexed citations

Carayol, Marion, Grégory Ninot, Pierre Sénesse, et al.. (2019). Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the “APAD1” randomized controlled trial. BMC Cancer. 19(1). 737–737. 89 indexed citations

Fraisse, Julien, Hélène de Forges, Marta Jarlier, et al.. (2018). Effects of a Hypnosis Session Before General Anesthesia on Postoperative Outcomes in Patients Who Underwent Minor Breast Cancer Surgery. JAMA Network Open. 1(4). e181164–e181164. 39 indexed citations

Courtinard, Coralie, Florence Bachelot, Anne Jaffré, et al.. (2017). Données de vraie vie en oncologie. Méthodologie de constitution d’une plateforme de données exhaustives multisources : l’exemple de la base ESME. Revue d Épidémiologie et de Santé Publique. 65. S49–S49. 2 indexed citations

Jacot, William, Nelly Firmin, Lise Roca, et al.. (2016). Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study. Annals of Oncology. 27(7). 1235–1241. 24 indexed citations

Assénat, Eric, D. Azria, Caroline Mollévi, et al.. (2015). Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial. Oncotarget. 6(14). 12796–12808. 54 indexed citations

Samalin, Emmanuelle, Christelle de la Fouchardière, Simon Thézenas, et al.. (2015). Triplet chemotherapy (TC) with FOLFIRINOX regimen in metastatic colorectal cancer (mCRC): Experience of two French centres.. Journal of Clinical Oncology. 33(3_suppl). 776–776. 1 indexed citations

Jacot, William, Simon Thézenas, Evelyne Lopez‐Crapez, et al.. (2013). BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. BMC Cancer. 13(1). 523–523. 47 indexed citations

10.

Carayol, Marion, Gilles Romieu, Jean‐Pierre Bleuse, et al.. (2013). Adapted physical activity and diet (APAD) during adjuvant breast cancer therapy: Design and implementation of a prospective randomized controlled trial. Contemporary Clinical Trials. 36(2). 531–543. 12 indexed citations

11.

Jacot, William, Stéphane Pouderoux, Simon Thézenas, et al.. (2012). Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 134(2). 709–717. 40 indexed citations

12.

Mazard, Thibault, Marc Ychou, Simon Thézenas, et al.. (2011). Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX. Cancer Chemotherapy and Pharmacology. 69(3). 807–814. 6 indexed citations

13.

Bleuse, Jean‐Pierre, Hielke J. Meulenbeld, Giordano Vitali, et al.. (2011). Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 29(15_suppl). 4628–4628. 2 indexed citations

14.

Jacot, William, Frédéric Bibeau, S. Gourgou-Bourgade, et al.. (2010). Phase II Trial of Dose Dense Docetaxel Followed by FEC100 as Neoadjuvant Chemotherapy in Patients With Operable Breast Cancer. American Journal of Clinical Oncology. 33(6). 544–549. 7 indexed citations

15.

Samalin, Emmanuelle, Françoise Desseigne, Simon Thézenas, et al.. (2009). 転移性結腸直腸癌(MCRC)患者の第一線治療としてのFOLFIRINOXと併用したセツキシマブを評価する多施設第二相試験の最終結果. Annals of Oncology. 20. 20. 2 indexed citations

16.

Abrial, Catherine, Frédérique Penault‐Llorca, R. Delva, et al.. (2006). High Prognostic Significance of Residual Disease After Neoadjuvant Chemotherapy: a Retrospective Study in 710 Patients with Operable Breast Cancer. Breast Cancer Research and Treatment. 98(3). 365–365. 4 indexed citations

17.

Abrial, Catherine, Frédérique Penault‐Llorca, R. Delva, et al.. (2005). High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Research and Treatment. 94(3). 255–263. 84 indexed citations

18.

Culine, Stéphane, Gilles Romieu, Michel Fabbro, et al.. (2004). Reducing the time interval between cycles using standard doses of docetaxel and lenogastrim support. Cancer. 101(1). 178–182. 4 indexed citations

19.

Trillet-Lenoir, V., François Chapuis, Sandrine Touzet, et al.. (2004). Any Clinical Benefit From the Use of Oncofoetal Markers in the Management of Chemotherapy for Patients with Metastatic Colorectal Carcinomas?. Clinical Oncology. 16(3). 196–203. 15 indexed citations

20.

Block, Stephan, et al.. (1998). [Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord].. PubMed. 85(6). 562–8. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact